doxorubicin + cyclophosphamide or docetaxel + cyclophosphamide

Doxorubicin + cyclophosphamide (AC) or docetaxel + cyclophosphamide (TC) refers to a treatment paradigm evaluated in the neoadjuvant setting for HER2-negative early-stage breast cancer. The AC regimen combines doxorubicin, an anthracycline that inhibits topoisomerase II and intercalates DNA, with cyclophosphamide, an alkylating agent that cross-links DNA strands. The TC regimen combines docetaxel, a taxane that stabilizes microtubules to inhibit mitosis, with cyclophosphamide. This specific "either/or" approach was the focus of a Duke University-sponsored Phase II trial (NCT00636441), which investigated whether genomic expression profiling could guide the selection between these two regimens to optimize the pathologic complete response rate in patients.

Brand names

Taxotere

Other names

AC regimenTC regimendoxorubicin and cyclophosphamidedocetaxel and cyclophosphamide